[Various therapy options. Medical Chemistry of platelet aggregation inhibitors]

Pharm Unserer Zeit. 2009;38(4):314-9. doi: 10.1002/pauz.200900320.

[Article in German]

Authors

Heiko Zettl¹, Manfred Schubert-Zsilavecz

Affiliation

¹ Johann Wolfgang Goethe-Universität, Frankfurt/Main.

PMID: 19572349
DOI: 10.1002/pauz.200900320

No abstract available

Publication types

Review

MeSH terms

Cyclooxygenase Inhibitors / pharmacology
Cyclooxygenase Inhibitors / therapeutic use
Dipyridamole / pharmacology
Dipyridamole / therapeutic use
Humans
Iloprost / pharmacology
Iloprost / therapeutic use
Platelet Aggregation / drug effects*
Platelet Aggregation Inhibitors / pharmacology
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Prostaglandin Antagonists / pharmacology
Prostaglandin Antagonists / therapeutic use
Purinergic P2 Receptor Antagonists
Thrombosis / drug therapy*
Thrombosis / prevention & control

Substances

Cyclooxygenase Inhibitors
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Prostaglandin Antagonists
Purinergic P2 Receptor Antagonists
Dipyridamole
Iloprost